Therapeutics and Clinical Risk Management

Older and newer players in the therapeutics of Cardio-Kidney-Metabolic syndrome

Cardio-Kidney-Metabolic (CKM) syndrome has been recently recognized by the American Heart Association (AHA) as the close interplay between cardiovascular disease (CVD), chronic kidney disease (CKD) and metabolic risk factors, mainly diabetes mellitus and obesity. CKM syndrome has attracted scientific attention due to its growing prevalence worldwide, reaching pandemic dimensions, whereas, several newer and novel therapeutic agents, targeting various pathophysiological aspects of CKM syndrome, have emerged over the last years, such as sodium-glucose co-transporter-2 (SGLT-2) inhibitors, incretin-based agents, tirzepatide, finerenone, and many other. The aim of this Article Collection is to gather scientific evidence regarding the impact of newer therapeutic agents on various components of CKM syndrome, as adjunct to established treatment options.